Liquid biopsy typically means blood testing, but several companies presenting at Biomed Israel May 21-23 have developed diagnostics that look to other, even less invasive options, and ever broader applications. Nevia Bio Ltd. is using vaginal secretions to detect ovarian cancer, while Early OM Ltd. and Nucleix Ltd. analyze urine for cancer biomarkers.
Shanghai Leadingtac Pharmaceutical Co. Ltd. has divulged proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a GTPase KRAS (G12D mutant) targeting moiety reported to be useful for the treatment of cancer.
Chengdu Zeling Biomedical Technology Co. Ltd. has identified poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of cancer.
Nine Square Therapeutics Inc. has disclosed mucolipin-1 modulators reported to be useful for the treatment of metabolic disease, neurodegeneration, aging, immunological disorders, inflammatory disorders, cardiovascular disorders, lysosomal storage disease and cancer.
Ygion Biomedical GmbH has completed a series A financing round of €15 million (US$ 16.3 million) to support the development of individualized neoantigen-based cancer vaccines.
Pheon Therapeutics Ltd. has completed a $120 million series B financing to fund the development of its pipeline of differentiated antibody-drug conjugates (ADCs) for cancer through clinical proof of concept.
Cancervax Inc. has announced that its University of California, Los Angeles (UCLA) research team has achieved a critical milestone by creating a process to add any antibody to lipid nanoparticles (LNPs) using click chemistry, for targeting cancer cells.
Researchers from Deutsches Krebsforschungszentrum DKFZ and affiliated organizations presented data for the novel inhibitor of DNA methyltransferase (DNMT) and histone methyltransferase G9a (HMT-G9a), CM-272, being developed for the treatment of acute myeloid leukemia (AML).
To strengthen its cancer pipeline, South Korea’s Dong-A ST Co. Ltd. made a strategic investment of ₩25 billion (US$18.45 million) in Seocho-gu, Seoul-based Idience Co. Ltd., a cancer-focused subsidiary of Ildong Pharmaceutical Co. Ltd. on May 20. The equity buyout makes Dongdaemun-gu, Seoul-based Dong-A ST the second largest shareholder of Idience, following Ildong Pharmaceutical. The two companies also shook on a co-development deal for Idience’s lead cancer asset, venadaparib (IDX-1197).
RSS
